Keywords: Adipose tissue; Antiretroviral therapy; CD4 T cells; Dolutegravir; HIV reservoirs; Tenofovir;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Abacavir; Lamivudine; Dolutegravir; Quality by design; Antiretroviral; Monte Carlo simulation; Normal operating range; Robustness;
Dolutegravir (DTG)-containing regimens after receiving raltegravir (RAL) or elvitegravir (EVG): Durability and virological response in a large Italian HIV drug resistance network (ARCA)
Keywords: Dolutegravir; Drug resistance; Genotype; Human immunodeficiency virus type 1; Durability; Virological response;
Cost Effectiveness of Dolutegravir as a First-Line Treatment Option in the HIV-1-Infected Treatment-Naive Patients in Russia
Keywords: cost effectiveness; dolutegravir; economic analyses; HIV; Russia;
Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen
Keywords: Residual viraemia; Elvitegravir/cobicistat; Dolutegravir; Non-nucleoside reverse transcriptase inhibitor; Integrase inhibitor; Protease inhibitor;
Impact of dolutegravir and efavirenz on immune recovery markers: results from a randomized clinical trial
Keywords: Antiretroviral therapy; CD4 percentage; CD4 T-cell count; CD4/CD8 ratio; dolutegravir; efavirenz;
Effect of dolutegravir in combination with Nucleoside Reverse Transcriptase Inhibitors (NRTIs) on people living with HIV who have pre-existing NRTI mutations
Keywords: HIV-1; Antiretroviral therapy; Nucleoside reverse transcriptase inhibitor; NRTI; Resistance; Dolutegravir;
Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistance
Keywords: ART; antiretroviral therapy; TasP; Treatment-as-Prevention; NRTI; nucleoside reverse transcriptase (RT) inhibitor; NNRTI; non-nucleoside RT inhibitor; PI; protease inhibitor; INSTI; integrase strand transfer inhibitor; RAL; raltegravir; EVG; elvitegravir;
The development and application of a novel LC–MS/MS method for the measurement of Dolutegravir, Elvitegravir and Cobicistat in human plasma
Keywords: Dolutegravir; Elvitegravir; Cobicistat; LC–MS/MS; Method validation
Development of a phenotypic susceptibility assay for HIV-1 integrase inhibitors
Keywords: HIV-1; Integrase; Phenotypic resistance; Geno2pheno; Cross-resistance; Dolutegravir;
Dolutegravir for the treatment of HIV-2 infection
Keywords: HIV-2; Dolutegravir; Raltegravir; Antiretroviral therapy; Drug resistance;
Dolutegravir-based antiretroviral therapy in a severely overweight child with a multidrug-resistant human immunodeficiency virus infection. A case report and review
Keywords: Children; dolutegravir; multidrug-resistant human immunodeficiency virus; rescue therapy; T-20
Development and validation of stability-indicating HPLC method for simeltaneous determination of Lamivudine, Tenofovir, and Dolutegravir in bulk and their tablet dosage form
Keywords: Gradient; Lamivudine; Tenofovir; Dolutegravir; Stability indicating
Discordant predictions of residual activity could impact dolutegravir prescription upon raltegravir failure
Keywords: dolutegravir; resistance; HIV-1; interpretation; integrase; treatment;
A liquid chromatography-tandem mass spectrometry assay for quantification of rilpivirine and dolutegravir in human plasma
Keywords: Mass spectrometry; Dolutegravir; Rilpivirine;
Dolutegravir does not affect methadone pharmacokinetics in opioid-dependent, HIV-seronegative subjects
Keywords: Dolutegravir; Methadone; Pharmacokinetics; Drug interaction;
Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients – Impact of HIV subtypes and prior raltegravir experience
Keywords: Dolutegravir; S/GSK1349572; Raltegravir; Integrase; Drug resistance; HIV subtypes